StockData

Roivant Sciences vs vTv Therapeutics

ROIV and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ROIV and VTVT compare

Roivant Sciences is the larger company, worth 409 times as much as vTv Therapeutics ($28.0B against $68.4M).

vTv Therapeutics grew revenue faster over the last twelve months (216600% versus −67.6% for Roivant Sciences).

vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −12.9% compared with −3535% at Roivant Sciences.

vTv Therapeutics scores higher on the StockData Score (11 against 7 for Roivant Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricROIVVTVT
Size and price
Market cap$28.0B$68.4M
Share price$38.71$17.29
Change, 1 year90.8%−43.9%
Change, 5 years453%−67.7%
Beta (5Y)0.420.08
Employees72126
StockData Score
Total score711 (better)
Valuation score03 (better)
Growth score01 (better)
Performance score12 (better)
Health score6 (better)5
Dividend score00
Valuation
P/S3712×1.9× (better)
P/B6.6×0.9× (better)
FCF yield−2.9%–
Fair value–$44.97
Margin of safety–61.6%
Growth
Revenue growth (TTM)−67.6%216600% (better)
Revenue growth, 5Y average−19.1%–
Profitability
Operating margin−7915%−25.1% (better)
Net margin−3535%−12.9% (better)
FCF margin−10901%–
Return on equity−6.2% (better)−11.7%
Return on invested capital−407%–
Financial health
Debt / equity0.000.00
Current ratio16.72 (better)12.48
Altman Z-score44.02 (better)0.71
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions78.1%40.6%
Held by insiders13.9%26.3%
Insider net buying, 12 months−$798M–
Superinvestors holding1–
Short interest, % of float7.3%5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.